Clinical Trials | November 24, 2025
Bayer’s experimental stroke drug could reshape secondary stroke prevention
Millions of stroke survivors across the world may soon have a new defense
Millions of stroke survivors across the world may soon have a new defense
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Glucagon-Like Peptide-1 is a natural hormone that regulates blood sugar, controls appetite, and slows digestion
Subscribe To Our Newsletter & Stay Updated
